A 64-year-old man presents to the clinic for a follow-up visit. Over the past four weeks, … — USMLE Step 3

A $64$ -year-old man presents to the clinic for a follow-up visit. Over the past four weeks, he has experienced progressive fatigue, an unintentional weight loss of $4$ kg ( $8.8$ lb), and intermittent palpitations. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of $30\%$ and recurrent sustained ventricular tachycardia. His medications include lisinopril, carvedilol, spironolactone, and amiodarone. He has been taking amiodarone for the past $2$ years. Vital signs show a blood pressure of $118/76$ mmHg and an irregularly irregular pulse of $112$ /min. Physical examination is notable for a fine resting tremor and warm, diaphoretic skin. The thyroid gland is not enlarged, and there is no tenderness to palpation.

Laboratory studies reveal the following:

Test	Result	Reference Range
Thyroid-stimulating hormone (TSH)	$<0.01$ $\mu$ U/mL	$0.4$ - $4.0$ $\mu$ U/mL
Free T4	$3.5$ ng/dL	$0.7$ - $1.9$ ng/dL
Free T3	$6.2$ pg/mL	$2.0$ - $4.4$ pg/mL

A color flow Doppler ultrasonography of the thyroid gland demonstrates a normal-sized gland with markedly decreased vascular flow.

Which of the following is the most appropriate next step in the pharmacologic management of this patient's thyroid dysfunction?

Initiate oral prednisoneAnswer
B
Initiate oral methimazole
C
Discontinue amiodarone immediately
D
Administer radioactive iodine ablation
E
Initiate oral levothyroxine

Answer

The correct answer is to initiate oral prednisone.

The correct answer is to initiate oral prednisone. This patient has developed amiodarone-induced thyrotoxicosis (AIT) during ongoing pharmacologic monitoring. Amiodarone is highly iodine-rich and can cause two distinct types of thyrotoxicosis. AIT type 1 typically occurs in patients with underlying thyroid disease (e.g., multinodular goiter) and is driven by excessive hormone synthesis fueled by the massive iodine load; color flow Doppler ultrasonography demonstrates increased vascularity. In contrast, AIT type 2 occurs in patients with a previously normal thyroid and represents a destructive thyroiditis caused by amiodarone's direct toxic effects on follicular cells. This destruction leads to the release of preformed thyroid hormone, and ultrasound classically demonstrates decreased vascularity. Because AIT type 2 is an inflammatory process rather than a state of true hyperthyroidism, the most appropriate pharmacologic treatment modification is the initiation of glucocorticoids, such as oral prednisone, to reduce inflammation and stabilize the follicular cells.

Step-by-Step Solution

Interpret the clinical presentation and laboratory findings to establish the primary complication of the patient's pharmacotherapy.

The patient has a suppressed TSH with elevated free T4 and T3, alongside symptoms of palpitations, weight loss, and tremor, confirming a diagnosis of thyrotoxicosis secondary to amiodarone.

Accurate interpretation of thyroid function tests is essential before adapting a high-risk medication regimen.

Analyze the color flow Doppler ultrasonography results to distinguish the specific subtype of toxicity.

The ultrasound demonstrates markedly decreased vascular flow, which differentiates amiodarone-induced destructive thyroiditis (type 2) from hyperthyroidism caused by increased hormone synthesis (type 1).

Amiodarone can cause two distinct types of thyrotoxicosis that mandate entirely different treatment modifications.

Select the appropriate pharmacologic management based on the toxicity subtype.

The patient has amiodarone-induced thyrotoxicosis (AIT) type 2. The standard of care is to initiate a glucocorticoid, such as oral prednisone, to suppress the inflammatory destruction of the thyroid follicles.

Unlike AIT type 1, which requires anti-thyroid drugs to block synthesis, AIT type 2 is an inflammatory condition that responds best to glucocorticoids.

Key Concept

Amiodarone-induced thyrotoxicosis type 2 is a destructive thyroiditis characterized by decreased vascularity on ultrasound and requires the initiation of glucocorticoids; it differs from type 1, which involves increased hormone synthesis and is treated with thionamides.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic